Description
Technical Information & Resources
Supporting Publications
Gellibert et al. (2004), Journal of Medicinal Chemistry
- This paper optimized a 1,5-naphthyridine screening hit into a series of potent, selective ALK5 (TGF-β type I receptor) inhibitors, one of which, RepSox, inhibited ALK5 autophosphorylation with an IC50 of 4 nM.
Ichida et al. (2009), Cell Stem Cell
- This paper demonstrated that RepSox inhibits Tgfbr1/ALK5 kinase activity to replace the Sox2 reprogramming factor by inducing endogenous Nanog expression in partially reprogrammed intermediate cells.
Bajpai et al. (2012), Cardiovasc Res
- This publication uses RepSox within a directed hiPSC differentiation protocol, guiding mesenchymal stem cell intermediates toward functional, contractile vascular smooth muscle cells.






